Can a drug cocktail revive immunotherapy for breast cancer?
NCT ID NCT05076682
First seen Jan 05, 2026 · Last updated Jun 20, 2026 · Updated 27 times
Summary
This phase 2 trial is testing several drug combinations (including choline, sodium cromoglicate, efavirenz, and others) alongside immunotherapy to see if they can reverse resistance in triple-negative breast cancer that has progressed after prior immunotherapy. About 80 participants with metastatic or locally advanced disease will be enrolled. The goal is to find a safe and effective way to make tumors respond again to treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
combination of drugs (choline, sodium cromoglicate, efavirenz, SHR-A1811, SHR-A2102, SHR-1316, mecapegfilgrastim, AK131, and others) plus an immune checkpoint inhibitor
What this could lead to
If it works, this could point toward a way to re-sensitize triple-negative breast cancer to immunotherapy, offering a new treatment option for patients who have stopped responding.
What could go wrong
This is an early phase 2 trial with only 80 participants and multiple drug combinations, so it is unclear which combination works best or if any will prove effective. Side effects from the drug cocktail may also be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.